ArticleThe Journal of antimicrobial chemotherapy2023

Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.

J B Readman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.